# Relmacabtagene autoleucel

Source: https://onco.cc/drugs/relmacabtagene-autoleucel/  
OnCo record `relmacabtagene-autoleucel` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments.

## Summary

Approved by the NMPA in September 2021 for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, three months after the Fosun Kite import of axicabtagene ciloleucel became China's first CAR-T approval; relapsed or refractory follicular lymphoma followed in 2022. The pivotal RELIANCE study (59 patients) reported an objective response rate of 75.9% and complete responses in 51.7%, with low rates of severe cytokine release syndrome. JW Therapeutics was formed in 2016 as a joint venture between Juno Therapeutics and WuXi AppTec, and the product is the Chinese sibling of lisocabtagene maraleucel.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: china
- Brand: Carteyva
- Code: relma-cel, JWCAR029
- Modality: Cell therapy (autologous CD19 CAR-T, 4-1BB)
- Mechanism: Autologous T cells transduced with a CD19-directed CAR (4-1BB co-stimulatory domain) derived from the JCAR017 construct, manufactured in Shanghai by JW Therapeutics.
- Approvals: China 2021: Relapsed or refractory large B-cell lymphoma after two or more lines; China 2022: Relapsed or refractory follicular lymphoma after two or more lines

## Sources

- JW Therapeutics: https://www.jwtherapeutics.com/en/
- RELIANCE (Cancer Med 2021): https://doi.org/10.1002/cam4.3686
- NMPA (National Medical Products Administration): https://www.nmpa.gov.cn

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [JW Therapeutics](https://onco.cc/companies/jw-therapeutics/), [WuXi AppTec](https://onco.cc/companies/wuxi-apptec/)
- trials: [CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma](https://onco.cc/trials/nct06479356/), [RELIANCE](https://onco.cc/trials/reliance/), [Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL](https://onco.cc/trials/nct06093841/)
- key papers: [Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China](https://onco.cc/key-papers/paper-ying-cancer-med/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/relmacabtagene-autoleucel.json